[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2023: 1.9
SJR 2023: 0.289
SNIP 2023: 0.327
Publication Charge
►Publication Fee
In Press
 In Press Articles
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 1 (Winter 2023) ::
Caspian J Intern Med 2023, 14(1): 47-52 Back to browse issues page
Resistance to Single-agent Chemotherapy for Low-risk Gestational Trophoblastic Neoplasia
Shahrzad Sheikhhasani , Aghdas Abdolrazaghnejad , Azam sadat Mousavi , Setareh Akhavan , Narges Zamani , Elham Feizabad
Department of Oncologic Gynecology, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran , dr.abdolrazaghnejad.gynecologist@gmail.com
Abstract:   (1560 Views)
Background: Methotrexate (MTX) and actinomycin D (ActD) have been used as first-line chemotherapy agents in the treatment of low-risk gestational trophoblastic neoplasia (GTN). Although low-risk GTN is considered a curable disease, its reported primary remission rates of 49 to 93% reflect the difficulties of treatment and different factors influencing it. Hence, this study aimed to determine the remission rates and related factors of single-agent chemotherapy resistance in low-risk GTN patients.
Methods: This retrospective study included patients with diagnosed low-risk GTN who received either MTX once a week (IM, 30mg/m2) or ActD once every two weeks (pulsed IV, 1.25mg/m2). Then, the patients were followed-up until complete remission or single-agent treatment failure to assess resistance rate and related factors.  
Results: Eighty-four patients were included in the study (18 patients were receiving MTX and 66 patients were receiving ActD). 85.7% of all participants achieved complete remission after first-line chemotherapy (72.2% in MTX vs 89.4% in ActD). There was a significant association for higher tumor size (P=0.046), the occurrence of metastasis (P=0.019), and pretreatment β-HCG levels (P=0.005) with resistance to treatment.
Conclusion: This study demonstrated higher tumor size, the occurrence of metastasis, and pretreatment β-HCG levels have been associated with increased resistance to first-line chemotherapy agents.
Keywords: Single-agent chemotherapy, Gestational trophoblastic neoplasia, Dactinomycin, Methotrexate, Treatment failure
Full-Text [PDF 292 kb]   (483 Downloads)    
Type of Study: Original Article | Subject: Oncology
Received: 2021/12/29 | Accepted: 2022/02/13 | Published: 2023/01/11
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sheikhhasani S, Abdolrazaghnejad A, Mousavi A S, Akhavan S, Zamani N, Feizabad E. Resistance to Single-agent Chemotherapy for Low-risk Gestational Trophoblastic Neoplasia. Caspian J Intern Med 2023; 14 (1) :47-52
URL: http://caspjim.com/article-1-3295-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 1 (Winter 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 40 queries by YEKTAWEB 4657